GAI-122 is being developed as IV administered formulation of an intracellular neuro-protectant that employs AlphaRx’s proprietary nano-emulsion formulation technology. More specifically, GAI-122 is being developed for the amelioration of stroke-induced injury and disability in China and as a preventive therapy for postoperative delirium in the US.
GAI-122, an investigational, injectable nanoemulsion of a Mitochondria-targeted neuro-protective agent formulated with AlphaRx’s proprietary drug delivery technology, has been shown to provide neuro-protection in multiple in-vitro and in-vivo animal studies, suggesting that this injectable nanoemulsion formulation has the potential to treat patients with acute ischemic stroke or to prevent postoperative delirium.
Michael Lee, president and CEO of AlphaRx, said: “We are very pleased with the progress of the GAI-122 development program; it is on track to enter human trials in 2010. The NINDS (National Institute of Neurological Disorders and Stroke) has recently initiated clinical trials using the oral form of GAI-122, for the treatment of Multiple Sclerosis. It further validated our clinical development strategy for GAI-122 as a neuro-protectant.”